Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in...

Por Vasiliki Chounta, Sonya J. Snedecor, Sterling Wu, Nicolas Van de Velde
Publicado em 2022-05-01

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis

Por Sonya J. Snedecor, Matthew Radford, David Kratochvil, Richard Grove, Yogesh S. Punekar
Publicado em 2019-05-01